Holen Sie sich die Stockscreener-App
0.8349
0.60%
0.005
Schlusskurs vom Vortag:
$0.8299
Offen:
$0.821
24-Stunden-Volumen:
158.87K
Relative Volume:
0.06
Marktkapitalisierung:
$8.93M
Einnahmen:
$1.52M
Nettoeinkommen (Verlust:
$-13.97M
KGV:
-0.2737
EPS:
-3.05
Netto-Cashflow:
$-13.29M
1W Leistung:
-2.42%
1M Leistung:
-5.14%
6M Leistung:
-7.10%
1J Leistung:
-19.72%
1-Tages-Spanne:
$0.8156
$0.8494
1-Wochen-Bereich:
$0.81
$0.91
52-Wochen-Spanne:
$0.55
$3.06
Predictive Oncology Inc Stock (POAI) Company Profile
Firmenname
Predictive Oncology Inc
Sektor
Telefon
412-432-1500
Adresse
91 43RD STREET, PITTSBURGH, MN
Vergleichen Sie POAI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
POAI
Predictive Oncology Inc
|
0.8324 | 8.93M | 1.52M | -13.97M | -13.29M | -3.05 |
|
ISRG
Intuitive Surgical Inc
|
543.18 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
171.56 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
88.20 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
256.88 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
217.45 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Predictive Oncology Inc Stock (POAI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-19 | Eingeleitet | H.C. Wainwright | Buy |
Predictive Oncology Inc Aktie (POAI) Neueste Nachrichten
Predictive Oncology Inc. (NASDAQ:POAI) Short Interest Up 50.6% in May - Defense World
Labcorp (LH) Gains Exclusive 3D Liver Models from Predictive Onc - GuruFocus
Predictive Oncology develops liver toxicity models for Labcor By Investing.com - Investing.com South Africa
Predictive Oncology Develops 3D Liver Toxicity Models for Labcorp - MarketScreener
Predictive Oncology Inc. Develops Functional 3D Organoid Models Exclusively for Labcorp - MarketScreener
Predictive Oncology develops liver toxicity models for Labcor - Investing.com Australia
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp - The Manila Times
Predictive Oncology Inc. Develops Exclusive 3D Organoid Models for Labcorp to Enhance Drug Discovery and Safety Evaluation - Nasdaq
Revolutionary 3D Organoid Models: How Predictive Oncology's Exclusive Labcorp Deal Transforms Drug Testing - Stock Titan
Predictive Oncology Faces Nasdaq Delisting Notice - TipRanks
Predictive Oncology (NASDAQ:POAI) Stock Price Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Major AI Breakthrough in Cancer Research: Leading Pharma Companies Unite in Revolutionary Oncology Initiative - Stock Titan
SEC Form 424B5 filed by Predictive Oncology Inc. - Quantisnow
'It's not something you choose to do, it's something you have to do': CEO & artist shares story - WTAE
Predictive Oncology (NASDAQ:POAI) Stock Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Court Denies Renovaro Motion for an Expedited Trial in July - GlobeNewswire
Predictive Oncology says court denies Renovaro motion for expedited trial - TipRanks
Predictive Oncology to defend against Renovaro’s claims in court By Investing.com - Investing.com Canada
Predictive Oncology (POAI) Addresses Legal Dispute with Renovaro - GuruFocus
Predictive Oncology to defend against Renovaro’s claims in court - Investing.com Australia
Court Denies Renovaro Motion for an Expedited Trial in July | POAI Stock News - GuruFocus
Delaware Court Rejects Renovaro's Rush to Trial Against Predictive Oncology, Cites Critical Delays - Stock Titan
Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger - MSN
Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish By Stocktwits - Investing.com India
UPDATERenovaro Inc. Announces Expedited Trial for 2025 Lawsui - GuruFocus
Predictive Oncology (POAI) Advances AI-Driven Cancer Drug Discov - GuruFocus
Renovaro Sues Predictive Oncology (POAI) Over Merger Agreement D - GuruFocus
Renovaro Gets Expedited Trial in Predictive Oncology Merger Dispute - marketscreener.com
Renovaro Sues Predictive Oncology (POAI) Over Merger Agreement Dispute | POAI Stock News - GuruFocus
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology - The Manila Times
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology | RENB Stock News - GuruFocus
Renovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger Agreement - Nasdaq
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to - GlobeNewswire
Court Fast-Tracks Renovaro's Lawsuit to Force Predictive Oncology Merger After 50% Stock Jump Drama - Stock Titan
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition | POAI Stock News - GuruFocus
Predictive Oncology harnesses AI for drug discovery - Investing.com
Predictive Oncology moves to leverage biobank using AI - TipRanks
Predictive Oncology harnesses AI for drug discovery By Investing.com - Investing.com Nigeria
Predictive Oncology Inc. Advances AI-Driven Drug Discovery with Extensive Biobank of Tumor Samples - Nasdaq
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition - GlobeNewswire
Major AI Breakthrough: How 150,000 Live Tumor Samples Are Revolutionizing Cancer Drug Discovery - Stock Titan
Predictive Oncology issued shareholder letter - TipRanks
Predictive Oncology (POAI) Showcases Recent Achievements and Future Plans | POAI Stock News - GuruFocus
Predictive Oncology Inc. Issues Shareholder Letter Titled, - GuruFocus
Predictive Oncology Expands AI-Driven Platform to Include Biomarker Discovery and Drug Repurposing for Precision Oncology - Nasdaq
Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: ... - Bluefield Daily Telegraph
Finanzdaten der Predictive Oncology Inc-Aktie (POAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):